ArticleScientific reports2026
Integrated bioactivity assessment of Syzygium aromaticum bud extract from Sudan shows antimicrobial and antioxidant potential.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory Review on Male Fertility Potential of Acetyl-Eugenol: Mechanistic Insights, Experimental Evidence, and Therapeutic Prospects.Journal of experimental pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating threat of antimicrobial resistance, coupled with the significant role of oxidative stress in chronic diseases, underscores the urgent need to identify novel multifunctional agents from natural sources to combat these issues. Clove (Syzygium aromaticum) is a well-known medicinal plant; however, comprehensive and standardized evaluations of its extracts are limited. This study provides an integrated pharmacological evaluation of an 80% ethanolic extract of clove (Syzygium aromaticum) buds. Phytochemical characterization revealed a rich composition, including high levels of total flavonoids (65.56 ± 0.05 mg QE/g) and phenolics (15.50 ± 0.02 mg GAE/g), along with alkaloids, tannins, and triterpenes content. The extract exhibited potent broad-spectrum antimicrobial activity against five standard strains (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, and Candida albicans), with inhibition zones ranging from 12.0 to 16.3 mm at 100 mg/mL. The minimum inhibitory concentration (MIC) values ranged from 390 to 780 µg/mL, and the minimum bactericidal/fungicidal concentration (MBC/MFC) ratios (≤ 4) confirmed a cidal mechanism of action. Activity Index analysis further highlighted its relative efficacy, demonstrating superior activity to erythromycin against E. coli (AI = 1.03) and moderate activity against other pathogens. In the antioxidant assessment, the extract outperformed the standard propyl gallate, showing 91 ± 0.03% DPPH radical scavenging activity and a significantly lower IC₅₀ (6.09 µg/mL vs. 17.39 µg/mL). Preliminary toxicity screening using the brine shrimp lethality assay indicated a favorable safety margin, with an LD₅₀ of 882.97 µg/mL (classified as slightly toxic), which was markedly higher (less toxic) than that of the control drug etoposide (LD₅₀ = 7.46 µg/mL). These findings underscore the potential of clove extract as a multifunctional natural agent against microbial infections and oxidative stress, offering a promising alternative for combating antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.